Characteristics of patients with thromboembolic events after treatment with PCCs
| Age, y . | Sex . | Anticoagulant . | Dose . | Indication . | Bleeding . | PCC dose, IU (IU/kg) . | Thromboembolism . | Timing from PCC, d . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 80 | Female | Rivaroxaban | 20 mg × 1 | SPAF | ICH | 1500 (29) | Stroke | 10 | Discharged. Died after 112 d of new stroke. |
| 71 | Female | Apixaban | 5 mg × 2 | SPAF | ICH | 2000 (27) | Stroke | 5 | Died after 18 d from ICH. |
| 73 | Male | Rivaroxaban | 20 mg × 1 | SPAF | ICH | 2000 (27) | Suspected PE* | 15 | Died after 16 d from ICH. |
| Age, y . | Sex . | Anticoagulant . | Dose . | Indication . | Bleeding . | PCC dose, IU (IU/kg) . | Thromboembolism . | Timing from PCC, d . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 80 | Female | Rivaroxaban | 20 mg × 1 | SPAF | ICH | 1500 (29) | Stroke | 10 | Discharged. Died after 112 d of new stroke. |
| 71 | Female | Apixaban | 5 mg × 2 | SPAF | ICH | 2000 (27) | Stroke | 5 | Died after 18 d from ICH. |
| 73 | Male | Rivaroxaban | 20 mg × 1 | SPAF | ICH | 2000 (27) | Suspected PE* | 15 | Died after 16 d from ICH. |
Diagnosis of pulmonary embolism was suspected clinically but never verified on imaging.